Healthcare Business

Why 4 Jefferies Franchise List Stocks Could Be Big Second-Half Winners

The company posted massive first-quarter results, and Jefferies now has a sizable $725 price target on the shares. The consensus target across Wall Street is even higher at $755, and the last Bio-Rad Laboratories stock trade on Friday came in at $601.68 a share.

CVS Health

This top stock for more conservative accounts offers a very solid entry point. CVS Health Corp. (NYSE: CVS) is one of the largest health care companies in the United States, providing retail, mail and specialty pharmacy dispensing services and pharmacy benefits. CVS has become one of the most vertically integrated publicly traded health care companies.

CVS serves employers, insurance companies, unions, government employee groups, health plans, prescription drug plans, Medicaid managed care plans, plans offered on public health insurance and private health insurance exchanges, other sponsors of health benefit plans and individuals. This segment operates retail specialty pharmacy stores and specialty mail order, mail order dispensing, and compounding pharmacies, as well as branches for infusion and enteral nutrition services.

CVS completed a $69 billion purchase of health care provider Aetna in November of 2018 and remains one of the top picks for 2021 and beyond, as CVS has become one of the most vertically integrated publicly traded health care companies

Investors in CVS Health stock receive a solid 2.35% dividend. The Jefferies price target is $95, while the posted consensus price target is $94.29. The shares ended Friday trading at $85.47 apiece.

Gilead Sciences

This stock is trading a very reasonable 9.75 times estimated 2021 earnings. Gilead Sciences Inc. (NASDAQ: GILD) is a biopharmaceutical company that discovers, develops and commercializes therapies for the treatment of HIV/AIDS, liver disease, cancer and inflammation. The acquisition of Kite Pharmaceutical in 2017 allowed for entry into the CAR-T space, indicating a renewed focus in oncology.

The company’s products include Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, Tybost and Vitekta for the treatment of human immunodeficiency virus (HIV) infection in adults, as well as Harvoni, Sovaldi, Viread and Hepsera products for the treatment of liver disease.

Gilead Sciences also offers Yescarta, Tecartus, Trodelvy and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, its Letairis is an oral formulation for the treatment of pulmonary arterial hypertension. Ranexa is an oral formulation for the treatment of chronic angina. AmBisome is a liposomal formulation for the treatment of serious invasive fungal infections.